SCHEMBL374345

SCHEMBL374345

CCN1CCN(Cc2cccc(N)c2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
KDM4E B2RXH2 3/20 0.59
TDP1 Q9NUW8 1/20 0.59
SIGMAR1 Q99720 4/20 0.49
PRMT6 Q96LA8 1/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 1/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
TP53 P04637 1/20 0.48
KMT2A Q03164 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
RAD52 P43351 2/20 0.46
GFER P55789 2/20 0.46
LMNA P02545 1/20 0.46
NCF1 P14598 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16760957 0.91 SIGMAR1 (0.56) ALDH1A1TDP1SIGMAR1PRMT6SMN1; SMN2
SCHEMBL62758 0.86 LMNA (0.64) SIGMAR1PRMT6NPC1RAB9ATP53
SCHEMBL29715963 0.86 LMNA (0.64) SIGMAR1PRMT6NPC1RAB9ATP53
Hydrochloric Acid SCHEMBL14999805 0.85 LMNA (0.62) SIGMAR1PRMT6NPC1RAB9ATP53
Hydrochloric Acid SCHEMBL1675838 0.85 LMNA (0.62) SIGMAR1PRMT6NPC1RAB9ATP53
Hydrochloric Acid SCHEMBL3974793 0.85 LMNA (0.62) SIGMAR1PRMT6NPC1RAB9ATP53
SCHEMBL13242846 0.84 PRMT6 (0.62) ALDH1A1KDM4ETDP1SIGMAR1PRMT6
SCHEMBL833409 0.84 PRMT6 (0.68) ALDH1A1KDM4ETDP1SIGMAR1PRMT6
SCHEMBL30469295 0.84 PRMT6 (0.68) ALDH1A1KDM4ETDP1SIGMAR1PRMT6
SCHEMBL13242878 0.83 SIGMAR1 (0.68) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104870446-B Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors 内尔维阿诺医学科学有限公司 2019-08-13 CN disclosed
CN-108047219-A Substituted pyrimidine radicals and Pyridylpyrrole and pyridinone, its preparation method and its purposes as kinase inhibitor 内尔维阿诺医学科学有限公司 2018-05-18 CN disclosed
CN-107205391-A Histone demethylase inhibitors 赛尔基因昆蒂赛尔研究公司 2017-09-26 CN disclosed
CN-101336237-B As the pyrimidinyl aryl urea derivatives of FGF inhibitor NOVARTIS AG (CH) 2015-09-30 CN disclosed
CN-104870446-A Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2015-08-26 CN disclosed
CN-103121972-B As the pyrimidine urea derivatives of kinase inhibitor NOVARTIS AG (CH) 2015-07-29 CN disclosed
EP-2418205-B1 Pyrimidine urea derivatives as kinase inhibitors NOVARTIS AG (CH) 2014-01-22 EP disclosed
US-8552002-B2 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea NOVARTIS AG (CH) 2013-10-08 US disclosed
EP-2409969-B1 Pyrimidine urea derivatives as kinase inhibitors NOVARTIS AG (CH) 2013-07-24 EP disclosed
CN-103121973-A Pyrimidine urea derivatives as kinase inhibitors NOVARTIS AG 2013-05-29 CN disclosed
US-20100179123-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-7601725-B2 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-7601725-B2 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-20090137804-A1 Compounds and Compositions as Protein Kinase Inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-05-28 US disclosed
US-20080319005-A1 Phenylacetamides Suitable as Protein Kinase Inhibitors NOVARTIS AG (CH) 2008-12-25 US disclosed
EP-1874770-A1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS Novartis Pharma AG (CH) 2008-01-09 EP disclosed
CN-101035769-A Pyrimidine urea derivatives as kinase inhibitors NOVARTIS AG (CH) 2007-09-12 CN disclosed
EP-1761505-A1 PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS Novartis AG (CH) 2007-03-14 EP disclosed
WO-2006108640-A1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2006-10-19 WO disclosed
WO-2006000420-A1 PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137804-A1 Compounds and Compositions as Protein Kinase Inhibitors MAP3K20, MAP3K1, CDK1 ALDH1A1 4285/4885KDM4E 1074/4885TDP1 915/4885
US-20100179123-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS AURKA, AURKB, AURKC ALDH1A1 3035/4885KDM4E 728/4885TDP1 98/4885
US-20080319005-A1 Phenylacetamides Suitable as Protein Kinase Inhibitors MAP3K20, MAP3K10, MAP3K9 ALDH1A1 2992/4885KDM4E 988/4885TDP1 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.